<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269252</url>
  </required_header>
  <id_info>
    <org_study_id>USA710-4003</org_study_id>
    <nct_id>NCT04269252</nct_id>
  </id_info>
  <brief_title>CHI-907 CBD Extract and Experiences of Test Anxiety</brief_title>
  <official_title>A Randomized Controlled Test of the Effects of CHI-907 on Experiences of Test Anxiety Among College Students</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canopy Health Innovations</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James Madison University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canopy Health Innovations</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled study examining the effects of CHI-907 on test
      anxiety specifically, and state anxiety more broadly.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal single-dose of CHI-907 to reduce test anxiety</measure>
    <time_frame>The test session visit is 3.5 hours long.</time_frame>
    <description>Subjects will report their level of test anxiety using the State Test Anxiety Visual Analog Scale (STAI-VAS) pre-test, mid-test, and post-test. The STAI-VAS is a measure from 0 (not anxious at all) to 100 (anxious).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal single-dose of CHI-907 to reduce test anxiety</measure>
    <time_frame>The test session visit is 3.5 hours long.</time_frame>
    <description>Subjects will report their level of test anxiety using the State Test Anxiety Visual Analog Scale (STAI-VAS) pre-test, mid-test, and post-test. The STAI-VAS is a measure from 0 (not anxious at all) to 100 (anxious).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>CHI-804 at 6 mL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard 6 mL dose of placebo oil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHI-907 at 1.5 mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are assigned to receive one dose of CHI-907.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHI-907 at 3 mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are assigned to receive one dose of CHI-907.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHI-907 at 6 mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are assigned to receive one dose of CHI-907.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHI-907</intervention_name>
    <description>CHI-907 is a high CBD extract.</description>
    <arm_group_label>CHI-907 at 1.5 mL</arm_group_label>
    <arm_group_label>CHI-907 at 3 mL</arm_group_label>
    <arm_group_label>CHI-907 at 6 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHI-804</intervention_name>
    <description>CHI-804 is the placebo formulation.</description>
    <arm_group_label>CHI-804 at 6 mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult between 18 and 55-years-old (inclusive).

          2. Willing and able to provide informed consent and attend a 2.5 hour, in-person session.

          3. Self-reports completing a college-level introductory level statistics class with a
             grade of &quot;C&quot; or better.

          4. Scores a 3.0 or higher on the Westside Test Anxiety Scale.

          5. Female of childbearing potential must not be pregnant or currently breastfeeding.

          6. If using medication, the student has maintained a stable regimen on existing
             medications for at least one month prior to participation in the study and throughout
             the study.

          7. Agrees to abide by all study restrictions and comply with all study procedures.

        Exclusion Criteria:

          1. Known history of significant allergic condition, significant hypersensitivity to the
             IP, or allergic reaction to cannabis, cannabinoid medications, or excipients of the
             investigational product.

          2. Exposed to any investigational drug or device &lt; 30 days prior to screening or plans to
             take an investigational drug in the near future.

          3. Used cannabis, synthetic cannabinoid or cannabinoid analogue, synthetic cannabinoid
             receptor agonist, or any CBD- or THC-containing product within 30 days of screening or
             during the study.

          4. Current or past primary DSM-5 diagnosis other than an anxiety disorder that the
             Investigator determines would interfere in testing or interfere in evaluation of the
             study testing.

          5. Total score of 8 or higher on the Alcohol Use Disorders Identification Test.

          6. Total score of 12 or higher on the Drug Abuse Screening Test.

          7. An acute or progressive disease that is likely to require changes in drug therapy
             during the study, or interfere with the objectives of the study, or the ability to
             adhere to protocol requirements.

          8. Currently prescribed medications with likely THC- or CBD- interactions.

          9. History of suicide attempt in the last year.

         10. Endorses current suicidal intent during the baseline assessment.

         11. Positive drug screen for THC, barbiturates, amphetamines, benzodiazepines, and/or
             opiates at baseline assessment.

         12. Clinically significant condition or abnormal findings during screening or the baseline
             assessment that would, in the opinion of the Investigator, preclude study
             participation or interfere with the evaluation of the study testing.

         13. Demonstrates behavior indicating unreliability or inability to comply with the
             requirements of the protocol.

         14. Female student of childbearing potential, unless willing to ensure that they or their
             partner use effective contraception during the study and for three months thereafter.

         15. Male student whose partner is of childbearing potential, unless willing to ensure that
             they or their partner use effective contraception during the study and for three
             months thereafter.

         16. Any other significant disease or disorder which, in the opinion of the investigator,
             may either put the student at risk because of participation in the study, may
             influence the result of the study, or affect the student's ability to participate in
             the study.

         17. History of diagnosis related to hepatic function and/or significantly impaired hepatic
             function (alanine aminotransferase [ALT] &gt;5 ´ upper limit of normal [ULN] or total
             bilirubin [TBL] &gt;2 ´ ULN) OR the ALT or aspartate aminotransferase (AST) &gt;3 ´ ULN and
             TBL &gt;2 ´ ULN (or international normalized ratio [INR] &gt;1.5).

         18. Plans for the student to travel outside their country of residence during the study.

         19. Body mass index (BMI) of underweight (18 kg/m2 and below) or obese (30 kg/m2 and
             above) or waist:hip ratio that is considered high health risk (0.86 and higher for
             women, 1.0 and higher for men).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Ware, MD</last_name>
    <role>Study Director</role>
    <affiliation>Canopy Health Innovations</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lia Casaca, `MA</last_name>
    <phone>647-930-2888</phone>
    <phone_ext>700</phone_ext>
    <email>lia.casaca@canopygrowth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Dumouchel, MA</last_name>
    <phone>647-930-2888</phone>
    <email>julie.dumouchel@canopygrowth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>James Madison University</name>
      <address>
        <city>Harrisonburg</city>
        <state>Virginia</state>
        <zip>22807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Irons, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Test Anxiety</keyword>
  <keyword>CBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

